Free Trial
ASX:PAR

Paradigm Biopharmaceuticals (PAR) Stock Price, News & Analysis

Paradigm Biopharmaceuticals logo

About Paradigm Biopharmaceuticals Stock (ASX:PAR)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
1.81 million shs
Average Volume
N/A
Market Capitalization
$196.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

Receive PAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paradigm Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PAR Stock News Headlines

Volatility Is Rising—But These 2 AI Stocks Could Thrive
2025 is off to a turbulent start—markets are swinging wildly, inflation pressures remain high, and recession fears are creeping back into headlines. But even in uncertain times, innovation doesn’t slow down. In fact, artificial intelligence (AI) is accelerating faster than ever—creating new profit opportunities while the broader market struggles. Our latest research reveals two AI stocks trading under $15 that could thrive even as volatility grows. These under-the-radar companies are positioned to ride the next wave of AI-driven demand—and they’re still flying below most investors’ radar.
See More Headlines

PAR Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Paradigm Biopharmaceuticals investors own include BHP Group (BHP), Electro Optic Systems (EOS), Mesoblast (MESO), CytoDyn (CYDY), Bubs Australia (BUB), Blue Energy (BLU) and BHP Group (BHP).

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
Computer Hardware
Current Symbol
ASX:PAR
CIK
N/A
Fax
N/A
Employees
1,480
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-58,650,000.00
Net Margins
-89,138.58%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$79,224.00
Price / Cash Flow
6.44
Book Value
A$0.08 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$196.66 million
Optionable
Not Optionable
Beta
0.94
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (ASX:PAR) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners